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The treatment of liver fibrosis has clinical limitations because of its multiple etiologies,
such as epithelial–mesenchymal transition (EMT) promotion, cell regeneration and
remodeling dysfunction, inflammatory cell activation, and scar tissue deposition. These
factors might be considered as a new target for the fibrotic microenvironment, leading
to increased fibrogenesis and liver fibrosis. Here, we investigate a small molecule
named butylidenephthalide (BP) and its multiple effects on liver fibrosis treatment.
Thioacetamide was used in vivo to induce chronic liver fibrosis. BP was administered
orally in rats for a period of 2 and 4 weeks, which resulted in a significantly reduced
fibrosis score (p < 0.05) and (p < 0.001), respectively. The inflammatory reaction of
macrophage infiltration were reduced in the administration of BP, which led to the
decrease in the transaminase levels. Moreover, we also found liver functions recovering
(due to the increased serum albumin and reduced prothrombin time) where liver cells
regenerated, which can be seen in the increase of Ki-67 on Oval cell. In addition, the
fibrotic scar was also reduced, along with the expression of matrix metalloprotease by
hepatic stellate cell. Furthermore, regarding the mechanism/study of EMT reduced by
BP, the knockdown of BMP-7, which could reduce α-SMA expression, was mediated
by the regulation of TGF-β, which implies its major role on EMT. Finally, in the in vivo
study, BP treatment of liver fibrosis was reduced by Bmp7 knockdown in zebrafish,
suggesting that BP leads to the reduction of liver fibrosis, which also depends on BMP-
7 induction. These results suggest that BP had multiple targets for treating liver fibrosis
in the following ways: reduction of EMT, decreasing inflammatory reaction, and liver cell
proliferation. This multiple targets approach provided a new mechanism to treat liver
injury and fibrosis.
Keywords: liver fibrosis, epithelial-messenchymal transition, hepatic stellate cells, regeneration,
microenvironment
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INTRODUCTION
The liver fibrosis occurs when there is an imbalanced state
characterized by increased fibrogenesis and decreased
fibrinolysis (Gunther et al., 1999), which results in the
accumulation of ECM proteins (e.g., collagens, fibronectin;
Kendall and Feghali-Bostwick, 2014). The recruitment of
myofibroblasts (Knittel et al., 1999a) and immune cells
(Bonacchi et al., 2003) by HSCs steadily increase the
fibrosis effect. The activated HSCs transdifferentiate into
myofibroblast-like cells through epithelial–mesenchymal
transition (EMT) (Choi and Diehl, 2009; Fan et al., 2015)
stimulates the secretion of transforming growth factor β
(TGF-β), which is the primary source of ECM modulator
(Liu et al., 2006). Bone morphogenetic protein 7 (BMP-7)
has been reported to have the opposite function of TGF-β
(Zeisberg et al., 2003; Weiskirchen et al., 2009); in addition,
it antagonizes the pathways of TGF-β so that it can have a
therapeutic potential (Henderson et al., 2013). Also, since
the liver is regenerative, the hepatic oval/progenitor cell
differentiates into the hepatocyte (Hindley et al., 2014)
and restore its function. Meanwhile, the regenerative
cells can replace impaired tissues and also secret matrix
metalloproteinases (Duarte et al., 2015) in order to digest
scar tissue. These effects seem to be essential in hepatic
restoration.
Butylidenephthalide (BP) is abundant in Chinese medicinal
herbs such as Angelica sinensis (Lao et al., 2004), and Ligusticum
chuanxiong (Chan et al., 2009). Studies have reported that
phthalide compounds perform an antiproliferative function
in HSCs through the inhibition of platelet-derived growth
factor (PDGF) (Lee et al., 2007), but in the in vivo data
on fibrosis, this has not yet been reported. In our previous
studies, BP was examined for antihepatocellular carcinoma
activity by inducing Nur77 (also known as NR4A1) expression,
which led to caspase-3-dependent apoptosis (Harn et al., 2011)
and triggered an antiplatelet effect through PDGF reduction
(Liu et al., 2011). BP also downregulates EMT-related genes
such as Snail (Snail/SNAI1) and Slug (Slug/SNAI2) (Yen
et al., 2015). Although EMT and tumor migration are the
characteristics of activated HSCs that cause liver fibrosis, these
considerations prompted us to study the effects of BP on liver
fibrosis.
Although the combination approach may solve the problem
in the current use of drugs (Trautwein et al., 2015), adequate
targeting designation is still a problem. One of the clinically
used drugs, Pentoxyfilline, was proven to have beneficial
effects on liver fibrosis (Satapathy et al., 2007). However, the
improvement in fibrosis was not statistically significant in
patients (Zein et al., 2011). In the current study, we found
BP has significantly shown improvement in reducing liver
fibrosis compared to Pentoxyfilline. In addition, BP has a
multi-function capacity that reduces EMT, decreases hepatic
inflammation, regenerates hepatic cells, and secretes matrix
metalloproteinase. These effects might be considered a new target
for the fibrotic microenvironment, and might be ineffective with
current drugs.
MATERIALS AND METHODS
Isolation of Hepatic Stellate Cells
The HSCs were isolated using the method described by Kawada
et al. (1993) with slight modification. In brief, the Wistar rats
were sacrificed, and then perfusion through portal vein with
Hank’s balanced salt solution (HBSS) was carried out. The liver
was cut off and minced rapidly, and incubated at 37◦C for
30 min with constant shaking under 0.05% collagenase I HBSS.
The digested liver was filtered through a 100-µm filter and
gauze and centrifuged at 50 × g for 5 min; the supernatant
was then collected and pelleted at 450 × g for 10 min. Density
centrifugation was performed at 1700× g for 15 min by an equal
volume of the suspension and 16.8% Histodenz (Sigma–Aldrich).
The HSCs were collected and washed with HBSS three times and
then seeded on a culture dish (1 × 107 cells). The cells were
cultured in DMEM containing 10% FBS and the medium was
replaced every other day for 2 weeks. Our animal studies were
approved by the China Medical University Institutional Animal
Care and Use Committee.
Cell Lines and Compound
The HSC-T6 cell line was kindly provided by Professor Friedman
of the Mount Sinai School of Medicine (New York, NY,
USA). Primary rat HSCs and HSC-T6 cells were maintained in
DMEM containing 10% FBS, 1% HEPES, 1% sodium pyruvate,
1% sodium bicarbonate, and 100 ng/mL of penicillin and
streptomycin. The cell culture media and supplements were
purchased from Thermo Scientific Hyclone (Logan, UT, USA).
The cells were cultured at 37◦C by using a 5% CO2 incubator. BP
(CAS 551-08-6) (MW = 188.23) was purchased from Lancaster
Synthesis Ltd. (Newgate Morecambe, UK) and dissolved in
dimethyl sulfoxide (DMSO) for cell culture. For the animal
studies, BP was dissolved in olive oil for oral administration.
Knockdown through siRNA Transfection
BMP-7 siRNA was synthesized by Thermo Scientific Dharmacon
(Lafayette, CO, USA). The TurboFect siRNA transfection reagent
was purchased from Fermentas Inc. (Glen Burnie, MD, USA).
To ensure that transfection was accurate, we used a pTY-EGFP
lentiviral vector carrying the EGFP reporter gene as a positive
control, and used 30 and 60 pmol of BMP-7 siRNA in each
transfection.
RNA Extraction and qRT-PCR Analysis
To isolate the RNA, the RNeasy RNA isolation kit was purchased
from QIAGEN (Valencia, CA, USA), and used according to the
manufacturer’s instruction. Complimentary DNA (cDNA) was
synthesized through reverse transcription of 1 µg of total RNA.
Primers were synthesized by Genomics BioSci & Tech (Taipei,
Taiwan) and are listed below. Bmp7 forward: 5′-GGTCGGCAG
GACTGGATCAT-3′, and reverse: 5′-ACCAGTGTCTGGACG
ATAGC-3′; acta forward:5′-CCGAGATCTCACCGACTACC-3′,
and reverse: 5′-TCCAGAGCGACATAGCACAG-3′; TGFb-
forward: 5′-TGACGTCACTGGAGTTGTCCGGCAG-3′, and
reverse: 5′-GGGCTTGCGACCCACGTAGTAGACA-3′; gapdh
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forward: 5′-AGCCCAGAACATCATCCCTG-3′; and reverse:
5′-CACCACCTTCTTGATGTCATC-3′. The parameters were
established by denaturing the cells at 95◦C for 1 min, annealing
the cells at 56◦C for 1 min, and executing extension at 72◦C for
2 min. The PCR products were separated on 2% agarose gels
and stained with ethidium bromide. For quantitative RT-PCR,
we used 50 ng RNA synthesized cDNA for each reaction by
Invitrogene SYBR R© GreenERTM qRT-PCR Kit (Logan, UT, USA)
and analyzed it on StepOnePlus Real-Time PCR system (Applied
Biosystems) or in 2% agarose gel followed by Ethidium bromide
staining.
Western Blot Analysis
Cells were lysed with PRO-PREP (iNtRON Biotechnology,
Gyeonggi-do, Korea) and incubated on ice for 15 min. The
chilled cells were centrifuged at 15 000 × g for 5 min, and the
supernatant was then quantified and electrophoresis performed.
After the proteins were transferred onto a polyvinylidene
fluoride membrane, blocking was then performed using 5%
skim milk. Primary antibodics against BMP-7 (orb100464)
was purchased from Biorbyt. Antibodies against TGF-β
(GTX110630), and collagen I (GTX20292) were purchased
from Genetex. Antibody against slug (9585) was purchased
from Cell Signaling Technology, and p-Smad 2/3 (sc-11769)
was purchased from Santa Cruz. These antibodies were 1000X
diluted into the blocking reagent and reacted overnight. The
membranes were washed three times with 0.1% Tween 20 in
phosphate-buffered saline (PBS; PBST) and incubated with
diluted secondary antibodies. All proteins were detected using
the Western Lightning Plus ECL reagent.
Establishment of the Rat Model of
Chronic Liver Fibrosis
To establish the rat model for chronic liver fibrosis, 200 mg/kg of
TAA (Sigma–Aldrich) was injected intraperitoneally into 8-week-
old male Wistar rats every 3 days, and normal saline was injected
simultaneously as a control. The therapeutic control entailed
using the pentoxifylline (50 mg/kg) to treat TAA-induced rats.
The rats were sacrificed on days 30, 45, and 60 for analysis (n= 4);
cardiac blood samples were collected to measure the biochemical
liver function index; liver samples were obtained, processed, and
sectioned to evaluate the histopathologic score. Histopathology
analysis was conducted as previously described by using H&E and
Masson’s trichrome stain (Harn et al., 2012). Liver tissue samples
were fixed for 2 days and fixation was in 10% buffered formalin.
The tissues were sectioned serially 4-µm of the processed tissue
and stained with H&E and Masson’s trichrome stain.
Establishment of the Fish Model of
Chronic Liver Fibrosis
Zebrafish were maintained according to the established protocols
of the Zebrafish International Resource Center. Embryos, larvae,
and adult fish were maintained in a tank system controlled
at 28◦C and supplied with a continuous flow of water, and
underwent an automated 14-h light and 10-h darkness cycle. The
feeding supplies included appropriate kind of food and frequency
which was according to the regular care and maintenance
protocol (Avdesh et al., 2012). To establish liver fibrosis, as
described by Rekha et al. (2008), we used 2-month-old zebrafish
and applied 300 mg/kg TAA intraperitoneal injections three
times per week for 4 weeks.
In Vivo Knockdown Using Morpholino in
Zebrafish
Vivo-MO is an siRNA conjugated with Morpholino specifically
targeting BMP-7 for in vivo studies, which was purchased from
Gene Tools, LLC (Philomath, OR, USA). To perform BMP-7
knockdown, MO was intravenously injected using a retro-orbital
injection technique (Pugach et al., 2009). Each fish was placed in
dorsal recumbency, on a wet sponge and swimming in tricaine
solution (4 mg/mL) to anesthetize the fish. The Hamilton syringe
was used to inject through the fish eyes and 5 µL was injected for
each fish.
Histopathological Analysis
For histopathological analysis, liver tissue samples were fixed in
3.7% formaldehyde for 2 days. The tissues were then dehydrated,
cleared, and infiltrated by automatic histoprocessor (Tissue-
Tek; Sakura, Tokyo, Japan) for 16 h. Serial 4-µm sections
of the processed tissue were stained with H&E and Masson’s
trichrome stain. For Masson’s trichrome staining, sections were
immersed in Bouin’s solution at 56◦C for 1 h and then stained
in Mayer’s hematoxylin solution for 5 min, in Biebrich scarlet–
acid fuchsin solution for 15 min, in phosphomolybdic acid–
phosphotungstic acid for 15 min, and in aniline blue for 5 min
(all reagents were purchased from Sigma–Aldrich, Steinheim,
Germany). The samples were dried and mounted on glass slides
and the sections were examined using a microscope (IX70;
Olympus Tokyo, Japan). The Metavir Scoring was evaluated by
a pathologist, as previously described (Harn et al., 2012). In
brief, the Metavir Score for liver fibrosis, were assigned to two
standardized numbers to grade on a 5-point scale for fibrosis
(F0∼F4) and 4-point scale for the amount of inflammation
(A0∼A3).
Immunohistochemical Staining
Paraffin sections were dehydrated in an oven before they were
stained, and were deparaffinized in xylene and rehydrated
through a graded series of ethanol solutions. Tissues were
blocked with a solution containing 5% milk and 1% bovine
serum albumin in PBS for 60 min at room temperature,
and subsequently incubated at 4◦C overnight with anti-
TGF-β, -BMP-7, -αSMA, and -Ki-67 antibodies (GeneTex,
USA). Secondary antibodies were hybridized, and visualized by
0.5 mg/mL of diaminobenzidine (DAB). Finally, the sections were
counterstained with hematoxylin and mounted, and each tissue
samples were randomly photographed at a magnification of 200×
by using an Aperio scanner (Leica Biosystems).
Zymography Analysis
MMPs activity were obtained by zymography analysis.
The supernatant was collected after 24 h treatment. The
Frontiers in Pharmacology | www.frontiersin.org 3 April 2016 | Volume 7 | Article 112
fphar-07-00112 April 27, 2016 Time: 18:15 # 4
Chuang et al. Butylidenephthalide Ameliorates Liver Fibrosis and Microenvironment
FIGURE 1 | Butylidenephthalide (BP) ameliorates hepatic fibrosis induced by TAA. Chronic liver fibrosis model and BP treatment for 2 months. Olive oil
treatment was performed as a vehicle treatment group, and the Pentoxfylline treatment (50 mg/kg) was the therapeutic group. Rats were sacrificed at 6th and 8th
week for evaluation of liver fibrosis. The Wistar rat were sacrificed on 4th, 6th, 8th weeks. Liver tissue was collected and indicated by H&E and Masson’s trichrome
stain. (A) Experimental protocol for liver fibrosis model and sacrifice points. Histology on (B) 6th week and (C) 8th week. The right side indicates arbitrary units by
using Aperio ePathology Software (n = 5 rat for each group; Original magnification was100×).
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samples buffered without 2-Mercaptoethanol and separated by
electrophoresis in a polyacrylamide gel containing 0.2% gelatin
(Sigma–Aldrich Co.) The gel was washed with washing buffer
(40 mM Tris-HCl pH 8.5, 0.2 M NaCl, 10 mM CaCl2, 2.5%
Triton X-100) twice for 30 min. The gel was incubated in the
reaction buffer (40 mM Tris-HCl pH 8.5, 0.2 M NaCl, 10 mM
CaCl2, 0.01% NaN3) over 16 h. The gel was then stained by
Coomassie blue (0.2% Coomassie blue R-250, 50% methanol,
10% acetic acid).
Statistical Analysis
In the RT-PCR analysis, quantification was conducted using
ImageJ (NIH, USA). The IHC positive stained areas were
measured using Image Scope (Leica Biosystems). Multiple groups
were subjected to a student t-test, and P ≤ 0.05 indicated the
statistical significance.
RESULTS
Butylidenephthalide Reduces Liver
Fibrosis in Thioacetamide-Treated Rats
To evaluate the antifibrosis effect of BP, we established a rat
model of liver fibrosis by intraperitoneally injecting the rats with
TAA (200 mg/kg body weight) twice per week for 8 weeks.
Four weeks after TAA injection, the rat model of liver fibrosis
was confirmed by histopathological analysis and randomly
grouped into the control, low, high dosage, and pentoxifylline
(50 mg/kg) groups. These rats were orally administered BP
(15 and 80 mg/kg) and olive oil daily for 15 and 30 d,
combined with TAA-injections, and the rats were subsequently
sacrificed. By using H&E stain, macrophage tissue infiltration
decreased in the BP treatment groups at 6th and 8th week
(activity score 1–2), whereas the olive oil group continued to
exhibit substantial cell infiltration (activity score 3–4) (Figure 1).
Masson’s trichrome stain for fibrotic tissue showed almost no
collagen accumulation in the BP treatment groups at weeks 6 and
8 (fibrosis grade 1–2), whereas the olive oil group still exhibited
a significant amount of collagen accumulation (fibrosis grade
2–3) (Figure 1C). The BP-treated groups exhibited significantly
reduced AST and ALT levels, as shown in Figure 1C and
1 day, respectively. These data suggest that BP administration
reduces both hepatic fibrosis and hepatic injury. BP reduced
fibrosis earlier and more effectively than those treated with
pentoxifylline.
Butylidenephthalide Treatment Reduces
Profibrogenic Proteins
TGF-β is the most important profibrogenic cytokine, which
induces EMT and causes fibrosis to occur. Thus, we analyzed
the expression of TGF-β and its antagonist, BMP-7, by using
immunohistochemistry. In the liver tissue, we observed the
expression of BMP-7 in nearly all of the livers, and TGF-β
was expressed only in the interlobular area (Figures 2A,B).
The expression of BMP-7 and TGF-β was quantified, and was
determined that the expression of BMP-7 was upregulated and
that TGF-β was downregulated (Figure 2C). These data are
consistent with the histopathological finding, suggesting that the
expression state may be related to the anti-fibrosis effect.
Butylidenephthalide Inhibits
Epithelial–Mesenchymal Transition in
Primary Rat Hepatic Stellate Cells
Gene expression in cells treated with BP at 15 µg/mL, 25 µg/mL,
or 35 µg/mL, or in a vehicle control, was analyzed using
semiquantitive RT-PCR (Figure 3A). The expression of BMP-7
increased in the BP-treated HSCs, whereas TGF-β and α-SMA
expression decreased in a dose-dependent manner. In the time-
dependent experiment, BMP-7 expression increased between 6
and 12 h, while TGF-β expression decreased between 12 and 24 h,
and lastly, the RNA expression of α-SMA decreased within 24 h.
Compared with the protein expression which was determined
using western blot analysis (Figure 3C), the expression of BMP-
7 and TGF-β was affected at 24 h, and the phosphorylation
of Smad 2/3 was reduced between 12 and 24 h. Studies have
reported that the downstream genes of TGF-β in the EMT were
induced through phospho-Smad (p-Smad) 2/3 and slug; the
EMT pathway was induced by BMP-7 and through E-cadherin
to reduce slug. BMP-7 was upregulated by BP at 6 h, and the
expression of TGF-β and slug decreased; previous studies have
obtained similar results indicating that slug is regulated by TGF-β
and serves as the key regulator in the EMT. In addition, TGF-
β-dependent p-Smad 2/3 was reduced by BP at 12 h, which
was later than the time in which TGF-β was affected, suggesting
that the EMT genes were regulated through p-Smad 2/3, a
downstream signal conductor of TGF-β. Furthermore, a study
TABLE 1 | Metavir scoring for hepatic fibrosis and serum biochemistry.
Activity Fibrosis AST ALT
6 Week 8 Week 6 Week 8 Week 6 Week 8 Week 6 Week 8 Week
Olive oil 2.95 ± 0.58 3.46 ± 0.36 3.2 ± 0.55 3.8 ± 0.45 307.7 ± 113.7 301.4 ± 92.76 115.8 ± 42.78 113.1 ± 29.41
PTX 50 mg 2.7b ± 0.15 3.31b ± 0.5 2.0a ± 0.43 2.83b ± 0.41 215.8a ± 44.02 180.8b ± 42.32 91.6c ± 19.85 76.74c ± 10.43
BP 15 mg 2.23a ± 0.36 1.98c ± 0.4 1.83c ± 0.41 1.98c ± 0.45 147.0c ± 32.19 160.7b ± 11.33 78.4c ± 28.48 84.18c ± 18.22
BP 80 mg 1.85c ± 0.92 1.55c ± 0.09 1.25c ± 0.5 1.17c ± 0.45 131.5c ± 21.18 95.7c ± 15.19 78.77c ± 16.23 101.9c ± 31.97
The serum levels of activity, fibrosis, AST, and ALT in TAA-induced rat. Metavir score indicates immune cells infiltration and tissue fibrosis by Masson’s trichrome and H&E
stain, respectively. BP administration was performed daily starting from the 4th week, samples were collected on 6th and 8th week points. (n = 5). (ap < 0.05, bp < 0.01,
cp < 0.001, Student’s t-test).
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FIGURE 2 | Butylidenephthalide-decreased the expression of TGF-β, but increased BMP-7 dose-dependently in liver tissues. The expression levels of
(A) BMP-7 and (B) TGF-β in BP-treated livers was evaluated using immunohistochemical staining. (C) The intensity quantification of positive area was obtained by
Aperio ePathology Software. Original magnification was 200×. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, Student’s t-test).
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reported that BMP-7 reverses the decrease of E-cadherin induced
by TGF-β, suggesting that BP inhibits the EMT pathways through
BMP-7 and TGF-β.
Bone Morphogenetic Protein 7
Knockdown Blocks
Butylidenephthalide-Inhibited
Epithelial–Mesenchymal Transition
Genes
Based on the in vitro data, we hypothesized that BP-
induced BMP-7 inhibits the development of fibrosis in a
A
B
C
FIGURE 3 | Butylidenephthalide reduces EMT-related gene expression
in dosage dependent manner in vivo and in cultured HSCs. Primary
HSCs treated with BP in (A) dosage-dependent manner using RT-PCR and
western blot analysis. (B) Time-dependent study for the RNA expressions of
BMP7, TGF-β, and α-SMA. (C) Western blot analysis to evaluated E- and
N-cadherin. The GAPDH and β-actin content demonstrate that equal
amounts of cDNA and protein had been loaded in each lane. The results
represent three independent experiments.
TAA-treated rat liver. To obtain additional evidence, we
examined BP-suppressed EMT in BMP-7-silenced HSCs by
using siRNA transfection. Accordingly, BMP-7 siRNA (30 or
60 pmol) was added to 35-mm dishes containing HSC-T6
cells. The cells were treated with 35 µg/mL of BP or a
vehicle control for 12 h, and mRNA expression was analyzed
using RT-PCR (Figure 4A) and quantitative PCR in three
independent transfections (Figure 4C). BMP-7 knockdown
enabled the successful recovery of TGF-β expression after
BP treatment, but α-SMA expression only slightly recovered,
indicating that BP targets BMP-7 and inhibits TGF-β. These
results were further confirmed by western blot analysis
(Figure 4B).
BP Suppresses Liver Fibrosis in
Zebrafish by Regulating Bone
Morphogenetic Protein 7
To demonstrate that BP suppressed liver fibrosis by regulating
BMP-7, we first developed TAA-induced liver fibrosis in
zebrafish (Figure 5A). The TAA-induced liver fibrosis was
obtained by performing intraperitoneal injections three times
a week (300 mg/kg) and with the treatment of BP in
the water of the aquarium. Fish liver was stained with
Masson’s, which indicated that TAA-induces fibrosis and it
was also ameliorated by BP (Figure 5B). BMP-7 knockdown
was treated by using morpholino (MO) and its expression
analyzed by RT-PCR. The BP-reduced liver fibrosis was
abolished by BMP-7 knockdown (Figure 5C), suggesting that
BP suppressed TAA induced liver fibrosis through BMP-7 in
zebrafish.
Butylidenephthalide Improves Liver
Function and Proliferation
The blood test for albumin and clotting time were analyzed
to evaluate liver functions, since albumin and clotting factors
are synthesized by the liver. As shown in Figure 6A,
serum albumin significantly increased in BP treatment groups.
Shortened prothrombin time indicates that the blood clotting
ability was enhanced between the control group and the BP
treatment group (Figure 6A, bottom). Liver cell regeneration
was revealed by analyzing the proliferation marker Ki-67
(Figure 6B). Furthermore, we analyzed the number of oval
cells which differentiated into hepatocytes (Figure 6C). Livers
administered with BP upregulated in their expression of Ki-
67 which resulted in liver regeneration in chronically damaged
liver.
Butylidenephthalide Induces
Matrix-Metalloproteinase Expression
and Activation
The ECM accumulation resulted in the progression of fibrosis.
In the liver regeneration stage, the improved liver cells secreted
matrix metalloproteinases, digest collagen, elastin, and gelatin.
To determine if BP can improve the digestion of ECM, we
used IHC to indicate MMP-9 expression in rat livers. In
Figure 7A, MMP-9 expression was upregulated on the 6th
Frontiers in Pharmacology | www.frontiersin.org 7 April 2016 | Volume 7 | Article 112
fphar-07-00112 April 27, 2016 Time: 18:15 # 8
Chuang et al. Butylidenephthalide Ameliorates Liver Fibrosis and Microenvironment
week by BP, whereas the control group stayed at the same
expression state. Furthermore, the activities of MMPs were
examined by zymography experiments. In previous reports,
HSC was considered as one of the MMP-secreted cells. Thus,
we used HSC-T6 cell lines to test the activity of MMPs. In
Figure 7B, BP induced MMP9 activity in a dose-dependent
manner, which is indicated by the digested gelatin (white
band).
FIGURE 4 | BMP-7 knock down recovered α-SMA and TGF-β expression. BP-induced BMP-7 secretion and BMP-7 knock down would reverse α-SMA
expression. BMP-7 knock down by BMP-7 siRNA also reduced the secretion of BMP-7. BMP-7 knock down and followed BP treatment for 24 h, using (A) RT-PCR
analysis for TGF-β, α-SMA, and BMP-7 expression. Further evidence by using (B) Western blot and (C) qRT-PCR to evaluate relative expressions. The relative
expression values were calculated with standard curve by StepOne software. (∗∗p < 0.01, ∗∗∗p < 0.001, Student’s t-test).
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FIGURE 5 | TAA-induced liver fibrosis in zebra fish. (A) Intraperitoneal injection of TAA (300 mg/kg) three times in a week. Liver tissues were then stained with
Masson’s trichrom stain. (B) The collagen content in liver was indicated in blue color. The upper showed TAA-induced liver fibrosis; the lower left showed a normal
liver, and lower right showed BP treated TAA-induced liver. (C) TAA-induced zebrafish was injected BMP-7 morpholino (MO) intravenously, and inhibited BP-induced
BMP-7 expression (left). Two samples were treated with TAA, BP, and combined with scrambled-morpholino or BMP-7-MO treatment (iv).
DISCUSSION
In recent years, many compounds have been reported to have
anti-fibrotic effects in liver cells of animal models, but few have
been approved for clinical use. A combined therapy treatment
of PTX and corticosteroids (CS) was thought to be good
because of its immune reaction, pro-inflammatory reduction,
and pro-fibrogenic cytokines reduction; CS alone has limited
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FIGURE 6 | Butylidenephthalide treatment improved liver function and proliferation. Serum albumin level and prothrombin times evaluate liver functions in
chronic liver fibrosis model. (A) Serum albumin content in 6 and 8 week rats treated with olive oil and BP. The lower graph showed that Prothrombin times
comparison of normal, olive oil, and BP treatment. (B) Ki-67 expression evaluated by IHC and intensity quantification between treatments. (C) Oval cell specific
marker OV-6 staining by IHC. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, Student’s t-test).
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effects (Sidhu et al., 2012). Sidhu et al. (2012) suggest the
PTX and CS combination therapy explains the importance
of anti-inflammatory could be less effectiveness as the anti-
fibrosis targets. Alternatively, not only do these drugs cause
inflammation and fibrotic cytokines, but it also reduces collagen
fiber digestion and cell regeneration; these play an important
role in the fibrotic microenvironment of the liver. Our results
support the potential for both effects to improve liver fibrosis.
As shown in Figures 1A–C and Table 1, the immune response
in the portal areas and the accumulation of collagen fiber were
reduced by BP. Moreover, BP downregulated EMT in Hepatic
stellate cell by reducing TGF-β expression mediated by BMP-
7 (Figures 2A,B), which led to decreasing collagen secretion.
Furthermore, liver stem cell of oval cell increased in proliferation
by BP. As a result, our data showed that the serum albumin
and prothrombin times of rats administered with BP returned
to their normal level (Figure 6A). We further found that BP
treatment induced MMP-9 expression and its enzyme activity
(Figures 7A,B), facilitates ECM degradation in the liver. In
summary, it can be concluded that BP caused multiple effects on
the microenvironment of the liver which led to liver fibrosis and
to the liver dysfunction.
In previous studies, renal and hepatic fibrosis models have
been shown to arise to about 40% of α-SMA–positive, collagen-
secreting myofibroblasts (Xu et al., 2014) from the differentiation
progenitors via EMT (Wynn and Ramalingam, 2012). EMT
inducers like TGF-β and BMP-7 can be targeted for therapy;
hence, we considered BP may reduce EMT, leading to the
improvement in liver fibrosis. In our time-dependent study
(Figure 3C), the protein expression of BMP-7 was upregulated
at an early stage (1 h after BP treatment), in contrast to TGF-
β, which decreased at the latter stage (12 h) of BP treatment.
Also, the RNA expression of bmp7 was induced at 0.5 to
1 h as shown in Figure 3B. These data reminds us that BP
induced BMP-7 can regulate the expression of TGF-β; thereby,
reducing liver fibrosis. To identify the relationship between
BMP-7 and TGF-β, we knocked down the expression of BMP-
7 by using siRNA and treated cells with BP for 24 h. We
observed that the downregulated expression of TGF-β was
partially recovered in BMP-7 knockdown cells, leading to an
increase in EMT, which has been reported to promote liver
fibrosis. Furthermore, to test whether BP reduces fibrosis in a
BMP-7 deficient liver, an in vivo study of a zebrafish liver fibrosis
model was conducted by administering TAA treatment (Rekha
et al., 2008). We observed that BP did not reduce fibrosis in
BMP-7 silenced fish (Figure 5C), suggesting that BMP-7 could
be the upstream regulator of TGF-β and EMT genes. These
results connect correlate? with previous studies on liver and renal
fibrosis (Zeisberg et al., 2003; Kinoshita et al., 2007; Yang et al.,
2012), suggesting that BMP-7 is one of the possible mechanisms
in reversing liver fibrosis by counteracting TGF-β and EMT
(Zeisberg et al., 2003).
In previous studies, MMP-9 (gelatinase B) was produced by
Kupffer cells, Hepatocytes, and HSCs (Knittel et al., 1999b). As
shown in Figure 6A, MMP-9 expression upregulated in 6w by
BP treatment, and it has a positive stain in the portal area.
Moreover, our results showed an increasing activity of MMP9
in the cultured HSC cells (Figure 7B). Hence, we hypothesized
FIGURE 7 | Butylidenephthalide treatment induces MMP9 expression and activity. MMP expression of fibrotic rat livers was indicated by IHC, with 6th, 8th
week treatment with BP or olive oil as control (A). In vitro study for MMP activity was demonstrated by zymography assay and secretion of HSC-T6 cells (B).
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that MMP-9 secretion was induced in HSC by BP, and then
the ECM was digested in the fibrotic livers. Unexpectedly, the
MMP-9 expression was also found in the olive oil treatment,
which is the solvent of BP used as the control of therapy.
However, the Masson’s stain indicates the area of fibrotic scarring,
which also expresses the MMP-9. Besides, previous reports
have revealed that the withdraw of TGF-β will enhance ECM
degradation and MMP activity (Arendt et al., 2005). In our
results, BP induced the secretion of active MMP-9 on 15 µg/ml
(Figure 7B); whereas, the dosage of reduction of TGF-β was
about 25∼35 µg/ml, suggesting that TGF-β reduction is actually
necessary in MMP-9-dependent ECM digestion. Furthermore,
BP treatment was dismissed in BMP7 deficient zebrafish, which
displayed collagen fibers in Masson’s stain. To summarize, BP
not only induced activity of MMP, but also reduced TGF-β to
facilitate metalloproteinase digestion. These findings suggest that
BP regulated the microenvironment in order for the liver fibrosis
to improve.
In summary, we demonstrated that BP reduced EMT by
regulating BMP-7 in order to ameliorate liver fibrosis. The
effect of MET was triggered by BMP-7 and inhibited by TGF-β,
and thus prevented the activation of HSC and α-SMA
expression. In addition, BP induced liver regeneration and
enabled the recovery of liver function. Third, BP induced
MMP-9 expression and fibrinolysis in the liver and reduced
previously accumulated collagen. These data suggest that
BP has the potential to effectively treat liver fibrosis
and target the liver microenvironment for its antifibrotic
effects.
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